Abbott Earnings Beat As Sales Growth Lags (ABT)
Abbott Laboratories (NYSE: ABT) may be in the midst of a long-term restructuring, but the company turned in earnings growth of 11.5% to $1.45 EPS. The analyst consensus estimate was $1.44 per share according to Thomson Reuters. Where this gets…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Abbott Laboratories (NYSE: ABT) may be in the midst of a long-term restructuring, but the company turned in earnings growth of 11.5% to $1.45 EPS. The analyst consensus estimate was $1.44 per share according to Thomson Reuters. Where this gets murky is that sales were light: $10.4 billion versus a consensus target of $10.63 billion, and that was after a 4.1% sales growth rate. The company’s adjusted gross margin ratio was almost 64% due to “improved efficiencies across a number of operating divisions, product mix, and the effect of foreign exchange.”
That “foreign exchange” is a wild card right now as companies have to hedge currencies and while the U.S. dollar is so strong (for a change).
We now have full 2012 guidance of $4.95 to $5.05 in earnings per share versus a consensus estimate from Thomson Reuters of $5.02 per share.
The company says that it is on track to separate into two companies for products and pharmaceuticals.
Abbott shares are indicated up 0.2% at $56.08 against a 52-week range of $45.07 to $56.84.
Contact [email protected] for any questions or corrections.